You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameKetamine
Accession NumberDB01221  (APRD00493)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionA cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (receptors, N-methyl-D-aspartate) and may interact with sigma receptors. [PubChem]
Structure
Thumb
Synonyms
(+-)-Ketamine
(±)-ketamine
2-(2-Chloro-phenyl)-2-methylamino-cyclohexanone
2-(methylamino)-2-(2-chlorophenyl)cyclohexanone
2-(o-chlorophenyl)-2-(methylamino)-cyclohexanone
DL-ketamine
Ketamina
KETAMINE
Ketaminum
NMDA
Special k
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ketalarinjection10 mg/mLintramuscular; intravenousPar Pharmaceutical, Inc.2007-10-01Not applicableUs
Ketalarsolution10 mgintramuscular; intravenousErfa Canada 2012 Inc1972-12-31Not applicableCanada
Ketalarinjection50 mg/mLintramuscular; intravenousPar Pharmaceutical, Inc.2007-10-01Not applicableUs
Ketalarsolution50 mgintramuscular; intravenousErfa Canada 2012 Inc1972-12-31Not applicableCanada
Ketalarinjection100 mg/mLintramuscular; intravenousPar Pharmaceutical, Inc.2007-10-01Not applicableUs
Ketalarinjection10 mg/mLintramuscular; intravenousGeneral Injectables & Vaccines, Inc2012-10-17Not applicableUs
Ketamine Hydrochlorideinjection100 mg/mLintravenousREMEDYREPACK INC.2015-06-18Not applicableUs
Ketamine Hydrochlorideinjection10 mg/mLintramuscular; intravenousPar Pharmaceutical Inc.2012-06-01Not applicableUs
Ketamine Hydrochlorideinjection50 mg/mLintramuscular; intravenousPar Pharmaceutical Inc.2012-06-01Not applicableUs
Ketamine Hydrochlorideinjection100 mg/mLintramuscular; intravenousPar Pharmaceutical Inc.2012-06-01Not applicableUs
Ketamine Hydrochloride Injection Sdzsolution50 mgintramuscular; intravenousSandoz Canada Incorporated2013-08-12Not applicableCanada
Ketamine Hydrochloride Injection Sdzsolution10 mgintramuscular; intravenousSandoz Canada IncorporatedNot applicableNot applicableCanada
Ketamine Hydrochloride Injection Sdzsolution50 mgintramuscular; intravenousSandoz Canada IncorporatedNot applicableNot applicableCanada
Ketamine Hydrochloride Injection USPsolution50 mgintramuscular; intravenousSandoz Canada Incorporated2003-02-04Not applicableCanada
Ketamine Hydrochloride Injection USPsolution10 mgintramuscular; intravenousSandoz Canada Incorporated2003-02-05Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ketamine Hydrochlorideinjection, solution10 mg/mLintramuscular; intravenousMylan Institutional LLC2013-06-04Not applicableUs
Ketamine Hydrochlorideinjection, solution, concentrate100 mg/mLintramuscular; intravenousHospira, Inc.1996-06-27Not applicableUs
Ketamine Hydrochlorideinjection, solution, concentrate50 mg/mLintramuscular; intravenousPhysicians Total Care, Inc.2002-03-12Not applicableUs
Ketamine Hydrochlorideinjection, solution, concentrate50 mg/mLintramuscular; intravenousHospira, Inc.1996-06-27Not applicableUs
Ketamine Hydrochlorideinjection, solution50 mg/mLintramuscular; intravenousMylan Institutional LLC2013-06-04Not applicableUs
Ketamine Hydrochlorideinjection, solution, concentrate50 mg/mLintramuscular; intravenousGeneral Injectables & Vaccines, Inc2012-10-11Not applicableUs
Ketamine Hydrochlorideinjection, solution100 mg/mLintramuscular; intravenousMylan Institutional LLC2013-06-04Not applicableUs
Ketamine Hydrochlorideinjection, solution, concentrate100 mg/mLintramuscular; intravenousGeneral Injectables & Vaccines, Inc2012-10-16Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
KetajectBristol-Myers Squibb
KetanestParke Davis
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Ketamine hydrochloride
1867-66-9
Thumb
  • InChI Key: VCMGMSHEPQENPE-UHFFFAOYNA-N
  • Monoisotopic Mass: 273.068719585
  • Average Mass: 274.186
DBSALT000396
Categories
UNII690G0D6V8H
CAS number6740-88-1
WeightAverage: 237.725
Monoisotopic: 237.092041846
Chemical FormulaC13H16ClNO
InChI KeyInChIKey=YQEZLKZALYSWHR-UHFFFAOYSA-N
InChI
InChI=1S/C13H16ClNO/c1-15-13(9-5-4-8-12(13)16)10-6-2-3-7-11(10)14/h2-3,6-7,15H,4-5,8-9H2,1H3
IUPAC Name
2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one
SMILES
CNC1(CCCCC1=O)C1=CC=CC=C1Cl
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as chlorobenzenes. These are compounds containing one or more chlorine atoms attached to a benzene moiety.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassHalobenzenes
Direct ParentChlorobenzenes
Alternative Parents
Substituents
  • Aralkylamine
  • Cyclohexylamine
  • Cyclohexanone
  • Chlorobenzene
  • Aryl halide
  • Aryl chloride
  • Cyclic ketone
  • Ketone
  • Secondary amine
  • Secondary aliphatic amine
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Carbonyl group
  • Amine
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor use as the sole anesthetic agent for diagnostic and surgical procedures that do not require skeletal muscle relaxation.
PharmacodynamicsKetamine is a rapid-acting general anesthetic producing an anesthetic state characterized by profound analgesia, normal pharyngeal-laryngeal reflexes, normal or slightly enhanced skeletal muscle tone, cardiovascular and respiratory stimulation, and occasionally a transient and minimal respiratory depression. Ketamine is indicated as the sole anesthetic agent for diagnostic and surgical procedures that do not require skeletal muscle relaxation. The anesthetic state produced by Ketamine has been termed “dissociative anesthesia” in that it appears to selectively interrupt association pathways of the brain before producing somesthetic sensory blockade. It may selectively depress the thalamoneocortical system before significantly obtunding the more ancient cerebral centers and pathways (reticularactivating and limbic systems).
Mechanism of actionKetamine has several clinically useful properties, including analgesia and less cardiorespiratory depressant effects than other anaesthetic agents, it also causes some stimulation of the cardiocascular system. Ketamine has been reported to produce general as well as local anaesthesia. It interacts with N-methyl-D-aspartate (NMDA) receptors, opioid receptors, monoaminergic receptors, muscarinic receptors and voltage sensitive Ca ion channels. Unlike other general anaesthetic agents, ketamine does not interact with GABA receptors.
Related Articles
AbsorptionRapidly absorbed following parenteral administration.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic.

SubstrateEnzymesProduct
Ketamine
NorketamineDetails
Ketamine
Not Available
6-HydroxyketamineDetails
Ketamine
Not Available
5-HydroxyketamineDetails
Ketamine
Not Available
4-HydroxyketamineDetails
Norketamine
Not Available
4-HydroxynorketamineDetails
Norketamine
Not Available
5-HydroxynorketamineDetails
Norketamine
Not Available
6-HydroxynorketamineDetails
6-Hydroxyketamine
Not Available
6-HydroxynorketamineDetails
5-Hydroxyketamine
Not Available
5-HydroxynorketamineDetails
4-Hydroxyketamine
Not Available
4-HydroxynorketamineDetails
Route of eliminationNot Available
Half life2.5-3 hours.
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9974
Blood Brain Barrier+0.9826
Caco-2 permeable+0.6326
P-glycoprotein substrateSubstrate0.5753
P-glycoprotein inhibitor INon-inhibitor0.5948
P-glycoprotein inhibitor IINon-inhibitor0.8383
Renal organic cation transporterNon-inhibitor0.6737
CYP450 2C9 substrateNon-substrate0.6363
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.7407
CYP450 1A2 substrateNon-inhibitor0.7323
CYP450 2C9 inhibitorNon-inhibitor0.7985
CYP450 2D6 inhibitorNon-inhibitor0.6912
CYP450 2C19 inhibitorNon-inhibitor0.5347
CYP450 3A4 inhibitorNon-inhibitor0.8253
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5426
Ames testNon AMES toxic0.7223
CarcinogenicityNon-carcinogens0.8878
BiodegradationNot ready biodegradable0.9937
Rat acute toxicity2.3939 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8859
hERG inhibition (predictor II)Inhibitor0.6047
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Injectionintramuscular; intravenous10 mg/mL
Injectionintramuscular; intravenous100 mg/mL
Injectionintramuscular; intravenous50 mg/mL
Solutionintramuscular; intravenous50 mg
Injectionintravenous100 mg/mL
Injection, solutionintramuscular; intravenous10 mg/mL
Injection, solutionintramuscular; intravenous100 mg/mL
Injection, solutionintramuscular; intravenous50 mg/mL
Injection, solution, concentrateintramuscular; intravenous100 mg/mL
Injection, solution, concentrateintramuscular; intravenous50 mg/mL
Solutionintramuscular; intravenous10 mg
Prices
Unit descriptionCostUnit
Ketamine hcl powder7.22USD g
Ketamine hcl-ns 50 mg/5 ml syr2.82USD ml
Ketamine 100 mg/ml vial2.36USD ml
Ketalar 100 mg/ml vial1.95USD ml
Ketamine hcl-ns 100 mg/10 ml1.95USD ml
Ketamine HCl 50 mg/ml Solution1.77USD ml
Ketalar 10 mg/ml vial0.99USD ml
Ketamine 10 mg/ml vial0.99USD ml
Ketalar 50 mg/ml vial0.75USD ml
Ketamine 50 mg/ml vial0.61USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point92-93U.S. Patent 3,254,124.
logP2.9Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0464 mg/mLALOGPS
logP2.69ALOGPS
logP3.35ChemAxon
logS-3.7ALOGPS
pKa (Strongest Acidic)18.78ChemAxon
pKa (Strongest Basic)7.45ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area29.1 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity65.55 m3·mol-1ChemAxon
Polarizability24.97 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

John A. Flores, Kenton L. Crowley, “Process for the preparation of ketamine ointment.” U.S. Patent US5817699, issued June, 1995.

US5817699
General References
  1. Harrison NL, Simmonds MA: Quantitative studies on some antagonists of N-methyl D-aspartate in slices of rat cerebral cortex. Br J Pharmacol. 1985 Feb;84(2):381-91. [PubMed:2858237 ]
  2. Bergman SA: Ketamine: review of its pharmacology and its use in pediatric anesthesia. Anesth Prog. 1999 Winter;46(1):10-20. [PubMed:10551055 ]
  3. Bonanno FG: Ketamine in war/tropical surgery (a final tribute to the racemic mixture). Injury. 2002 May;33(4):323-7. [PubMed:12091028 ]
  4. Lankenau SE, Sanders B, Bloom JJ, Hathazi D, Alarcon E, Tortu S, Clatts MC: First injection of ketamine among young injection drug users (IDUs) in three U.S. cities. Drug Alcohol Depend. 2007 Mar 16;87(2-3):183-93. Epub 2006 Sep 18. [PubMed:16979848 ]
  5. Reboso Morales JA, Gonzalez Miranda F: [Ketamine]. Rev Esp Anestesiol Reanim. 1999 Mar;46(3):111-22. [PubMed:10228376 ]
External Links
ATC CodesN01AX03
AHFS Codes
  • 28:04.00
  • 28:04.92
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (67.5 KB)
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when Ketamine is combined with 7-Nitroindazole.
AbirateroneThe serum concentration of Ketamine can be increased when it is combined with Abiraterone.
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Ketamine.
AcepromazineThe risk or severity of adverse effects can be increased when Ketamine is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Ketamine is combined with Aceprometazine.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Ketamine.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Ketamine.
adipiplonThe risk or severity of adverse effects can be increased when Ketamine is combined with adipiplon.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Ketamine.
AgomelatineThe risk or severity of adverse effects can be increased when Ketamine is combined with Agomelatine.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Ketamine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Ketamine is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Ketamine.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Ketamine.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Ketamine is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Ketamine.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Ketamine.
AmiodaroneThe metabolism of Ketamine can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Ketamine is combined with Amisulpride.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Ketamine.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Ketamine.
AmobarbitalThe risk or severity of adverse effects can be increased when Ketamine is combined with Amobarbital.
AmoxapineThe risk or severity of adverse effects can be increased when Ketamine is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Ketamine is combined with Amperozide.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Ketamine.
AprepitantThe serum concentration of Ketamine can be increased when it is combined with Aprepitant.
AripiprazoleThe risk or severity of adverse effects can be increased when Ketamine is combined with Aripiprazole.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Ketamine.
ArticaineThe risk or severity of adverse effects can be increased when Ketamine is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Ketamine is combined with Asenapine.
AtazanavirThe metabolism of Ketamine can be decreased when combined with Atazanavir.
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Ketamine.
AtenololThe serum concentration of Atenolol can be increased when it is combined with Ketamine.
AtomoxetineThe metabolism of Ketamine can be decreased when combined with Atomoxetine.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Ketamine.
AzaperoneThe risk or severity of adverse effects can be increased when Ketamine is combined with Azaperone.
AzelastineKetamine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Ketamine.
BaclofenThe risk or severity of adverse effects can be increased when Ketamine is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Ketamine is combined with Barbital.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Ketamine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Ketamine is combined with Benzyl alcohol.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Ketamine.
BexaroteneThe serum concentration of Ketamine can be decreased when it is combined with Bexarotene.
BoceprevirThe metabolism of Ketamine can be decreased when combined with Boceprevir.
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Ketamine.
BortezomibThe metabolism of Ketamine can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Ketamine can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Ketamine.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Ketamine.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Ketamine is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ketamine.
BrimonidineThe risk or severity of adverse effects can be increased when Ketamine is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Ketamine is combined with Bromazepam.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Ketamine.
BrompheniramineThe risk or severity of adverse effects can be increased when Ketamine is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Ketamine is combined with Brotizolam.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Ketamine.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Ketamine.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Ketamine.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Ketamine.
ButacaineThe risk or severity of adverse effects can be increased when Ketamine is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Ketamine is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Ketamine is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Ketamine is combined with Butethal.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Ketamine.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Ketamine.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Ketamine.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Ketamine.
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Ketamine.
CapecitabineThe metabolism of Ketamine can be decreased when combined with Capecitabine.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Ketamine.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Ketamine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Ketamine is combined with Carfentanil.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Ketamine.
CarisoprodolThe risk or severity of adverse effects can be increased when Ketamine is combined with Carisoprodol.
CelecoxibThe metabolism of Ketamine can be decreased when combined with Celecoxib.
CeritinibThe serum concentration of Ketamine can be increased when it is combined with Ceritinib.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Ketamine.
CetirizineThe risk or severity of adverse effects can be increased when Ketamine is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Ketamine is combined with Chloral hydrate.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Ketamine.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Ketamine.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Ketamine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Chlorphenamine.
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Ketamine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Ketamine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Ketamine is combined with Chlorprothixene.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Ketamine is combined with Chlorzoxazone.
CholecalciferolThe metabolism of Ketamine can be decreased when combined with Cholecalciferol.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Ketamine.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Ketamine.
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Ketamine.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Ketamine.
CitalopramThe risk or severity of adverse effects can be increased when Ketamine is combined with Citalopram.
CitalopramThe metabolism of Ketamine can be decreased when combined with Citalopram.
ClarithromycinThe metabolism of Ketamine can be decreased when combined with Clarithromycin.
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Ketamine.
ClemastineThe metabolism of Ketamine can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Ketamine is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Ketamine is combined with Clidinium.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Ketamine.
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Ketamine.
clomethiazoleThe risk or severity of adverse effects can be increased when Ketamine is combined with clomethiazole.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Ketamine.
ClomipramineThe risk or severity of adverse effects can be increased when Ketamine is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Ketamine is combined with Clonazepam.
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Ketamine.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Ketamine.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Ketamine.
ClopidogrelThe metabolism of Ketamine can be decreased when combined with Clopidogrel.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Ketamine.
ClotrimazoleThe metabolism of Ketamine can be decreased when combined with Clotrimazole.
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Ketamine.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Ketamine.
CobicistatThe metabolism of Ketamine can be decreased when combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Ketamine.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Ketamine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Ketamine.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Ketamine.
ConivaptanThe serum concentration of Ketamine can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Ketamine.
CrizotinibThe metabolism of Ketamine can be decreased when combined with Crizotinib.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Ketamine.
CyclizineThe risk or severity of adverse effects can be increased when Ketamine is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ketamine.
CyclosporineThe metabolism of Ketamine can be decreased when combined with Cyclosporine.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Ketamine.
CyproheptadineThe risk or severity of adverse effects can be increased when Ketamine is combined with Cyproheptadine.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Ketamine.
DabrafenibThe serum concentration of Ketamine can be decreased when it is combined with Dabrafenib.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Ketamine.
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Ketamine.
DantroleneThe risk or severity of adverse effects can be increased when Ketamine is combined with Dantrolene.
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Ketamine.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Ketamine.
DapoxetineThe risk or severity of adverse effects can be increased when Ketamine is combined with Dapoxetine.
DarunavirThe metabolism of Ketamine can be decreased when combined with Darunavir.
DasatinibThe serum concentration of Ketamine can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Ketamine.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Ketamine.
DeferasiroxThe serum concentration of Ketamine can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Ketamine can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when Ketamine is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Ketamine.
DesipramineThe risk or severity of adverse effects can be increased when Ketamine is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Ketamine is combined with Desloratadine.
DetomidineThe risk or severity of adverse effects can be increased when Ketamine is combined with Detomidine.
DexamethasoneThe serum concentration of Ketamine can be decreased when it is combined with Dexamethasone.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Ketamine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Ketamine is combined with Dexbrompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Ketamine.
DextromoramideThe risk or severity of adverse effects can be increased when Ketamine is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Ketamine.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Ketamine.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Ketamine.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Ketamine.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Ketamine.
DifenoxinThe risk or severity of adverse effects can be increased when Ketamine is combined with Difenoxin.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Ketamine.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Ketamine.
DihydrocodeineThe risk or severity of adverse effects can be increased when Ketamine is combined with Dihydrocodeine.
DihydroergotamineThe metabolism of Ketamine can be decreased when combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Ketamine is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Ketamine is combined with Dihydromorphine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Ketamine.
DiltiazemThe metabolism of Ketamine can be decreased when combined with Diltiazem.
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Ketamine.
DimenhydrinateThe risk or severity of adverse effects can be increased when Ketamine is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Ketamine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Ketamine.
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Ketamine.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Ketamine.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Ketamine.
DoramectinThe risk or severity of adverse effects can be increased when Ketamine is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Ketamine is combined with Doxepin.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Ketamine.
DoxorubicinThe metabolism of Ketamine can be decreased when combined with Doxorubicin.
DoxycyclineThe metabolism of Ketamine can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Ketamine.
DoxylamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Ketamine is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Ketamine.
DronedaroneThe metabolism of Ketamine can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Ketamine.
DrotebanolThe risk or severity of adverse effects can be increased when Ketamine is combined with Drotebanol.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Ketamine.
EcgonineThe risk or severity of adverse effects can be increased when Ketamine is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Ketamine is combined with ECGONINE METHYL ESTER.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Ketamine.
EfavirenzThe serum concentration of Ketamine can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Ketamine is combined with Efavirenz.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Ketamine.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Ketamine.
EntacaponeThe risk or severity of adverse effects can be increased when Ketamine is combined with Entacapone.
EnzalutamideThe serum concentration of Ketamine can be decreased when it is combined with Enzalutamide.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Ketamine.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Ketamine.
ErythromycinThe metabolism of Ketamine can be decreased when combined with Erythromycin.
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Ketamine.
EscitalopramThe risk or severity of adverse effects can be increased when Ketamine is combined with Escitalopram.
Eslicarbazepine acetateThe serum concentration of Ketamine can be decreased when it is combined with Eslicarbazepine acetate.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Ketamine.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Ketamine.
EstriolThe serum concentration of Estriol can be increased when it is combined with Ketamine.
EstroneThe serum concentration of Estrone can be increased when it is combined with Ketamine.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Ketamine.
EthanolKetamine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Ketamine.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ketamine.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Ketamine.
EthosuximideThe risk or severity of adverse effects can be increased when Ketamine is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Ketamine is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ketamine is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ketamine is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Ketamine is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Ketamine is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Ketamine is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Ketamine is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Ketamine.
EtoperidoneThe risk or severity of adverse effects can be increased when Ketamine is combined with Etoperidone.
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Ketamine.
EtorphineThe risk or severity of adverse effects can be increased when Ketamine is combined with Etorphine.
EtravirineThe serum concentration of Ketamine can be decreased when it is combined with Etravirine.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Ketamine.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Ketamine.
EzogabineThe risk or severity of adverse effects can be increased when Ketamine is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Ketamine is combined with Felbamate.
FelodipineThe metabolism of Ketamine can be decreased when combined with Felodipine.
FencamfamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Fencamfamine.
FenfluramineThe risk or severity of adverse effects can be increased when Ketamine is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ketamine.
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Ketamine.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Ketamine.
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Ketamine.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Ketamine.
FlibanserinThe risk or severity of adverse effects can be increased when Ketamine is combined with Flibanserin.
FloxuridineThe metabolism of Ketamine can be decreased when combined with Floxuridine.
FluconazoleThe metabolism of Ketamine can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Ketamine is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Ketamine is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Ketamine is combined with Flunitrazepam.
FluorouracilThe metabolism of Ketamine can be decreased when combined with Fluorouracil.
FluoxetineThe risk or severity of adverse effects can be increased when Ketamine is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Ketamine.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Ketamine.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Ketamine.
FluspirileneThe risk or severity of adverse effects can be increased when Ketamine is combined with Fluspirilene.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Ketamine.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Ketamine is combined with Fluticasone Propionate.
FluvastatinThe metabolism of Ketamine can be decreased when combined with Fluvastatin.
FluvoxamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Fluvoxamine.
FluvoxamineThe metabolism of Ketamine can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Ketamine can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Ketamine can be increased when it is combined with Fosaprepitant.
FosphenytoinThe risk or severity of adverse effects can be increased when Ketamine is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Ketamine is combined with Fospropofol.
Fusidic AcidThe serum concentration of Ketamine can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Ketamine.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Ketamine is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Ketamine is combined with Gamma Hydroxybutyric Acid.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Ketamine.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Ketamine.
GemfibrozilThe metabolism of Ketamine can be decreased when combined with Gemfibrozil.
GlutethimideThe risk or severity of adverse effects can be increased when Ketamine is combined with Glutethimide.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Ketamine.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Ketamine.
GuanfacineThe risk or severity of adverse effects can be increased when Ketamine is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Ketamine.
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Ketamine.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Ketamine.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Ketamine.
HeroinThe risk or severity of adverse effects can be increased when Ketamine is combined with Heroin.
HexobarbitalThe risk or severity of adverse effects can be increased when Ketamine is combined with Hexobarbital.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Ketamine.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Ketamine.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Ketamine.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ketamine.
HydroxyzineThe risk or severity of adverse effects can be increased when Ketamine is combined with Hydroxyzine.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Ketamine.
IdelalisibThe serum concentration of Ketamine can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Ketamine is combined with Iloperidone.
ImatinibThe metabolism of Ketamine can be decreased when combined with Imatinib.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Ketamine.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Ketamine.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Ketamine.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Ketamine.
IndalpineThe risk or severity of adverse effects can be increased when Ketamine is combined with Indalpine.
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Ketamine.
IndinavirThe metabolism of Ketamine can be decreased when combined with Indinavir.
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Ketamine.
IrbesartanThe metabolism of Ketamine can be decreased when combined with Irbesartan.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Ketamine.
IsavuconazoniumThe metabolism of Ketamine can be decreased when combined with Isavuconazonium.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Ketamine.
IsradipineThe metabolism of Ketamine can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Ketamine can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Ketamine can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Ketamine.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Ketamine.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Ketamine.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketamine is combined with Ketobemidone.
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Ketamine.
KetoconazoleThe metabolism of Ketamine can be decreased when combined with Ketoconazole.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Ketamine.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Ketamine.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Ketamine.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Ketamine.
LapatinibThe metabolism of Ketamine can be decreased when combined with Lapatinib.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Ketamine.
LeflunomideThe metabolism of Ketamine can be decreased when combined with Leflunomide.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Ketamine.
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Ketamine.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Ketamine.
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Ketamine.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Ketamine.
LevocabastineThe risk or severity of adverse effects can be increased when Ketamine is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Ketamine is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Ketamine is combined with Levodopa.
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Ketamine.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Ketamine is combined with Levomethadyl Acetate.
LevomilnacipranThe risk or severity of adverse effects can be increased when Ketamine is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Ketamine.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Ketamine.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Ketamine.
LithiumThe risk or severity of adverse effects can be increased when Ketamine is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Ketamine is combined with Lofentanil.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Ketamine.
LopinavirThe metabolism of Ketamine can be decreased when combined with Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Ketamine is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Ketamine.
LosartanThe serum concentration of Losartan can be increased when it is combined with Ketamine.
LosartanThe metabolism of Ketamine can be decreased when combined with Losartan.
LovastatinThe metabolism of Ketamine can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Ketamine.
Lu AA21004The risk or severity of adverse effects can be increased when Ketamine is combined with Lu AA21004.
LuliconazoleThe serum concentration of Ketamine can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Ketamine can be decreased when it is combined with Lumacaftor.
LurasidoneThe risk or severity of adverse effects can be increased when Ketamine is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Ketamine.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Ketamine is combined with Magnesium Sulfate.
MannitolThe serum concentration of Mannitol can be increased when it is combined with Ketamine.
MaprotilineThe risk or severity of adverse effects can be increased when Ketamine is combined with Maprotiline.
MeclizineThe risk or severity of adverse effects can be increased when Ketamine is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Ketamine is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Ketamine.
MelperoneThe risk or severity of adverse effects can be increased when Ketamine is combined with Melperone.
MemantineThe risk or severity of adverse effects can be increased when Ketamine is combined with Memantine.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Ketamine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Ketamine.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Ketamine.
MetaxaloneThe risk or severity of adverse effects can be increased when Ketamine is combined with Metaxalone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Ketamine.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Ketamine is combined with Methadyl Acetate.
MethapyrileneThe risk or severity of adverse effects can be increased when Ketamine is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Ketamine is combined with Methaqualone.
MethocarbamolThe risk or severity of adverse effects can be increased when Ketamine is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Ketamine.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Ketamine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Ketamine is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Ketamine.
MethsuximideThe risk or severity of adverse effects can be increased when Ketamine is combined with Methsuximide.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Ketamine.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Ketamine.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Ketamine.
MetyrosineKetamine may increase the sedative activities of Metyrosine.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Ketamine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Ketamine.
MifepristoneThe metabolism of Ketamine can be decreased when combined with Mifepristone.
MilnacipranThe risk or severity of adverse effects can be increased when Ketamine is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ketamine.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Ketamine.
MirtazapineKetamine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Ketamine.
MitotaneThe serum concentration of Ketamine can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Ketamine.
ModafinilThe serum concentration of Ketamine can be decreased when it is combined with Modafinil.
MolindoneThe risk or severity of adverse effects can be increased when Ketamine is combined with Molindone.
MorphineThe serum concentration of Morphine can be increased when it is combined with Ketamine.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Ketamine.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Ketamine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Ketamine.
NabiloneThe risk or severity of adverse effects can be increased when Ketamine is combined with Nabilone.
NadololThe serum concentration of Nadolol can be increased when it is combined with Ketamine.
NafcillinThe serum concentration of Ketamine can be decreased when it is combined with Nafcillin.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Ketamine.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Ketamine.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Ketamine.
NefazodoneThe metabolism of Ketamine can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Ketamine can be decreased when combined with Nelfinavir.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Ketamine.
NetupitantThe serum concentration of Ketamine can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Ketamine can be decreased when combined with Nevirapine.
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Ketamine.
NicardipineThe metabolism of Ketamine can be decreased when combined with Nicardipine.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Ketamine.
NilotinibThe metabolism of Ketamine can be decreased when combined with Nilotinib.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Ketamine.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Ketamine.
NitrazepamThe risk or severity of adverse effects can be increased when Ketamine is combined with Nitrazepam.
Nitrous oxideThe risk or severity of adverse effects can be increased when Ketamine is combined with Nitrous oxide.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Ketamine.
NormethadoneThe risk or severity of adverse effects can be increased when Ketamine is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Ketamine is combined with Nortriptyline.
OlanzapineThe risk or severity of adverse effects can be increased when Ketamine is combined with Olanzapine.
OlaparibThe metabolism of Ketamine can be decreased when combined with Olaparib.
OlopatadineThe risk or severity of adverse effects can be increased when Ketamine is combined with Olopatadine.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Ketamine.
OmeprazoleThe metabolism of Ketamine can be decreased when combined with Omeprazole.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Ketamine.
OpiumThe risk or severity of adverse effects can be increased when Ketamine is combined with Opium.
OrphenadrineKetamine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Ketamine.
OsanetantThe risk or severity of adverse effects can be increased when Ketamine is combined with Osanetant.
OsimertinibThe serum concentration of Ketamine can be increased when it is combined with Osimertinib.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Ketamine.
OxprenololThe risk or severity of adverse effects can be increased when Ketamine is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Ketamine.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ketamine.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Ketamine.
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Ketamine.
PalbociclibThe serum concentration of Ketamine can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Ketamine is combined with Paliperidone.
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Ketamine.
ParaldehydeKetamine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Ketamine.
ParoxetineThe risk or severity of adverse effects can be increased when Ketamine is combined with Paroxetine.
ParoxetineThe metabolism of Ketamine can be decreased when combined with Paroxetine.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Ketamine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Ketamine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Ketamine.
PerampanelThe risk or severity of adverse effects can be increased when Ketamine is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Ketamine is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Ketamine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Ketamine.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Ketamine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Ketamine.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Ketamine is combined with Phenoxyethanol.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Ketamine.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Ketamine.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Ketamine.
PioglitazoneThe metabolism of Ketamine can be decreased when combined with Pioglitazone.
PipamperoneThe risk or severity of adverse effects can be increased when Ketamine is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Ketamine is combined with Pipotiazine.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Ketamine.
PizotifenThe risk or severity of adverse effects can be increased when Ketamine is combined with Pizotifen.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Ketamine.
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Ketamine.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Ketamine.
PosaconazoleThe metabolism of Ketamine can be decreased when combined with Posaconazole.
PramipexoleKetamine may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Ketamine is combined with Pramocaine.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Ketamine.
PrazepamThe risk or severity of adverse effects can be increased when Ketamine is combined with Prazepam.
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Ketamine.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Ketamine.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Ketamine.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Ketamine.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Ketamine.
PrimidoneThe risk or severity of adverse effects can be increased when Ketamine is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Ketamine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ketamine.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Ketamine.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Ketamine.
PromethazineThe risk or severity of adverse effects can be increased when Ketamine is combined with Promethazine.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Ketamine.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Ketamine.
PropoxycaineThe risk or severity of adverse effects can be increased when Ketamine is combined with Propoxycaine.
PropranololThe serum concentration of Propranolol can be increased when it is combined with Ketamine.
ProtriptylineThe risk or severity of adverse effects can be increased when Ketamine is combined with Protriptyline.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Ketamine.
PSD502The risk or severity of adverse effects can be increased when Ketamine is combined with PSD502.
PyrimethamineThe metabolism of Ketamine can be decreased when combined with Pyrimethamine.
QuazepamThe serum concentration of Ketamine can be increased when it is combined with Quazepam.
QuazepamThe risk or severity of adverse effects can be increased when Ketamine is combined with Quazepam.
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Ketamine.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ketamine.
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Ketamine.
QuinineThe serum concentration of Quinine can be increased when it is combined with Ketamine.
QuinineThe metabolism of Ketamine can be decreased when combined with Quinine.
RabeprazoleThe metabolism of Ketamine can be decreased when combined with Rabeprazole.
RamelteonThe risk or severity of adverse effects can be increased when Ketamine is combined with Ramelteon.
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Ketamine.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Ketamine.
RanolazineThe metabolism of Ketamine can be decreased when combined with Ranolazine.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ketamine.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Ketamine.
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Ketamine.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Ketamine.
RifabutinThe metabolism of Ketamine can be increased when combined with Rifabutin.
RifampicinThe metabolism of Ketamine can be increased when combined with Rifampicin.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Ketamine.
RifapentineThe metabolism of Ketamine can be increased when combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Ketamine.
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Ketamine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Ketamine.
RitonavirThe metabolism of Ketamine can be decreased when combined with Ritonavir.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Ketamine.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Ketamine.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Ketamine.
RomifidineThe risk or severity of adverse effects can be increased when Ketamine is combined with Romifidine.
RopiniroleKetamine may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Ketamine.
RosiglitazoneThe metabolism of Ketamine can be decreased when combined with Rosiglitazone.
RotigotineKetamine may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Ketamine.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Ketamine is combined with S-Ethylisothiourea.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Ketamine.
SaquinavirThe metabolism of Ketamine can be decreased when combined with Saquinavir.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Ketamine.
ScopolamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Ketamine.
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Ketamine.
SertindoleThe risk or severity of adverse effects can be increased when Ketamine is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Ketamine is combined with Sertraline.
SertralineThe metabolism of Ketamine can be decreased when combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Ketamine is combined with Sevoflurane.
SildenafilThe metabolism of Ketamine can be decreased when combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Ketamine.
SiltuximabThe serum concentration of Ketamine can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Ketamine can be increased when it is combined with Simeprevir.
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Ketamine.
Sodium oxybateThe risk or severity of adverse effects can be increased when Ketamine is combined with Sodium oxybate.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Ketamine.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Ketamine.
SorafenibThe metabolism of Ketamine can be decreased when combined with Sorafenib.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Ketamine.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Ketamine.
St. John's WortThe serum concentration of Ketamine can be decreased when it is combined with St. John's Wort.
StiripentolThe risk or severity of adverse effects can be increased when Ketamine is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ketamine.
SulfadiazineThe metabolism of Ketamine can be decreased when combined with Sulfadiazine.
SulfamethoxazoleThe metabolism of Ketamine can be decreased when combined with Sulfamethoxazole.
SulfisoxazoleThe metabolism of Ketamine can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Ketamine.
SuvorexantThe risk or severity of adverse effects can be increased when Ketamine is combined with Suvorexant.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Ketamine.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Ketamine.
TamoxifenThe metabolism of Ketamine can be decreased when combined with Tamoxifen.
TapentadolThe risk or severity of adverse effects can be increased when Ketamine is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Ketamine is combined with Tasimelteon.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Ketamine.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Ketamine.
TelaprevirThe metabolism of Ketamine can be decreased when combined with Telaprevir.
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Ketamine.
TelithromycinThe metabolism of Ketamine can be decreased when combined with Telithromycin.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Ketamine.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Ketamine.
TeriflunomideThe metabolism of Ketamine can be decreased when combined with Teriflunomide.
TetrabenazineThe risk or severity of adverse effects can be increased when Ketamine is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Ketamine is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Ketamine is combined with Tetrodotoxin.
ThalidomideKetamine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Ketamine.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Ketamine.
ThiopentalThe risk or severity of adverse effects can be increased when Ketamine is combined with Thiopental.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Ketamine.
ThiotepaThe metabolism of Ketamine can be decreased when combined with Thiotepa.
ThiothixeneThe risk or severity of adverse effects can be increased when Ketamine is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Ketamine is combined with Tiagabine.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Ketamine.
TicagrelorThe metabolism of Ketamine can be decreased when combined with Ticagrelor.
TiclopidineThe metabolism of Ketamine can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Tiletamine.
TimololThe serum concentration of Timolol can be increased when it is combined with Ketamine.
TizanidineThe risk or severity of adverse effects can be increased when Ketamine is combined with Tizanidine.
TocilizumabThe serum concentration of Ketamine can be decreased when it is combined with Tocilizumab.
TolbutamideThe metabolism of Ketamine can be decreased when combined with Tolbutamide.
TolcaponeThe risk or severity of adverse effects can be increased when Ketamine is combined with Tolcapone.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Ketamine.
TopiramateThe risk or severity of adverse effects can be increased when Ketamine is combined with Topiramate.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Ketamine.
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Ketamine.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Ketamine.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ketamine.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Ketamine.
TrazodoneThe risk or severity of adverse effects can be increased when Ketamine is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Ketamine.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ketamine.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Ketamine.
TrimethoprimThe metabolism of Ketamine can be decreased when combined with Trimethoprim.
TrimipramineThe risk or severity of adverse effects can be increased when Ketamine is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Ketamine is combined with Triprolidine.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Ketamine.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Ketamine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Ketamine.
ValsartanThe metabolism of Ketamine can be decreased when combined with Valsartan.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Ketamine.
VenlafaxineThe metabolism of Ketamine can be decreased when combined with Venlafaxine.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Ketamine.
VerapamilThe metabolism of Ketamine can be decreased when combined with Verapamil.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Ketamine.
VigabatrinThe risk or severity of adverse effects can be increased when Ketamine is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Ketamine is combined with Vilazodone.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Ketamine.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Ketamine.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Ketamine.
VoriconazoleThe metabolism of Ketamine can be decreased when combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Ketamine is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Ketamine is combined with Xylazine.
ZafirlukastThe metabolism of Ketamine can be decreased when combined with Zafirlukast.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Ketamine.
ZiconotideThe risk or severity of adverse effects can be increased when Ketamine is combined with Ziconotide.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Ketamine.
ZimelidineThe risk or severity of adverse effects can be increased when Ketamine is combined with Zimelidine.
ZiprasidoneThe metabolism of Ketamine can be decreased when combined with Ziprasidone.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ketamine is combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Ketamine is combined with Zolazepam.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Ketamine.
ZonisamideThe risk or severity of adverse effects can be increased when Ketamine is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Ketamine.
ZotepineThe risk or severity of adverse effects can be increased when Ketamine is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Ketamine is combined with Zuclopenthixol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein phosphatase 2a binding
Specific Function:
NMDA receptor subtype of glutamate-gated ion channels with reduced single-channel conductance, low calcium permeability and low voltage-dependent sensitivity to magnesium. Mediated by glycine. May play a role in the development of dendritic spines. May play a role in PPP2CB-NMDAR mediated signaling mechanism (By similarity).
Gene Name:
GRIN3A
Uniprot ID:
Q8TCU5
Molecular Weight:
125464.07 Da
References
  1. Smothers CT, Woodward JJ: Pharmacological characterization of glycine-activated currents in HEK 293 cells expressing N-methyl-D-aspartate NR1 and NR3 subunits. J Pharmacol Exp Ther. 2007 Aug;322(2):739-48. Epub 2007 May 14. [PubMed:17502428 ]
  2. Harrison NL, Simmonds MA: Quantitative studies on some antagonists of N-methyl D-aspartate in slices of rat cerebral cortex. Br J Pharmacol. 1985 Feb;84(2):381-91. [PubMed:2858237 ]
  3. Sinner B, Graf BM: Ketamine. Handb Exp Pharmacol. 2008;(182):313-33. doi: 10.1007/978-3-540-74806-9_15. [PubMed:18175098 ]
  4. Radovanovic D, Pjevic M: [Ketamine: the past 30 years and its future]. Med Pregl. 2003 Sep-Oct;56(9-10):439-45. [PubMed:14740534 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Tachykinin receptor activity
Specific Function:
This is a receptor for the tachykinin neuropeptide substance P. It is probably associated with G proteins that activate a phosphatidylinositol-calcium second messenger system. The rank order of affinity of this receptor to tachykinins is: substance P > substance K > neuromedin-K.
Gene Name:
TACR1
Uniprot ID:
P25103
Molecular Weight:
46250.5 Da
References
  1. Okamoto T, Minami K, Uezono Y, Ogata J, Shiraishi M, Shigematsu A, Ueta Y: The inhibitory effects of ketamine and pentobarbital on substance p receptors expressed in Xenopus oocytes. Anesth Analg. 2003 Jul;97(1):104-10, table of contents. [PubMed:12818951 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonistpartial agonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Seeman P, Guan HC, Hirbec H: Dopamine D2High receptors stimulated by phencyclidines, lysergic acid diethylamide, salvinorin A, and modafinil. Synapse. 2009 Aug;63(8):698-704. doi: 10.1002/syn.20647. [PubMed:19391150 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurot...
Gene Name:
OPRD1
Uniprot ID:
P41143
Molecular Weight:
40368.235 Da
References
  1. Smith DJ, Pekoe GM, Martin LL, Coalgate B: The interaction of ketamine with the opiate receptor. Life Sci. 1980 Mar 10;26(10):789-95. [PubMed:6246318 ]
  2. Hustveit O, Maurset A, Oye I: Interaction of the chiral forms of ketamine with opioid, phencyclidine, sigma and muscarinic receptors. Pharmacol Toxicol. 1995 Dec;77(6):355-9. [PubMed:8835358 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Norepinephrine:sodium symporter activity
Specific Function:
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A2
Uniprot ID:
P23975
Molecular Weight:
69331.42 Da
References
  1. Salt PJ, Barnes PK, Beswick FJ: Inhibition of neuronal and extraneuronal uptake of noradrenaline by ketamine in the isolated perfused rat heart. Br J Anaesth. 1979 Sep;51(9):835-8. [PubMed:508488 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synthetic opioids and for the psychoactive diterpene salvinorin A. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates th...
Gene Name:
OPRK1
Uniprot ID:
P41145
Molecular Weight:
42644.665 Da
References
  1. Smith DJ, Pekoe GM, Martin LL, Coalgate B: The interaction of ketamine with the opiate receptor. Life Sci. 1980 Mar 10;26(10):789-95. [PubMed:6246318 ]
  2. Hustveit O, Maurset A, Oye I: Interaction of the chiral forms of ketamine with opioid, phencyclidine, sigma and muscarinic receptors. Pharmacol Toxicol. 1995 Dec;77(6):355-9. [PubMed:8835358 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Voltage-gated calcium channel activity
Specific Function:
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone. Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociati...
Gene Name:
OPRM1
Uniprot ID:
P35372
Molecular Weight:
44778.855 Da
References
  1. Smith DJ, Pekoe GM, Martin LL, Coalgate B: The interaction of ketamine with the opiate receptor. Life Sci. 1980 Mar 10;26(10):789-95. [PubMed:6246318 ]
  2. Hustveit O, Maurset A, Oye I: Interaction of the chiral forms of ketamine with opioid, phencyclidine, sigma and muscarinic receptors. Pharmacol Toxicol. 1995 Dec;77(6):355-9. [PubMed:8835358 ]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Components:
NameUniProt IDDetails
Muscarinic acetylcholine receptor M1P11229 Details
Muscarinic acetylcholine receptor M2P08172 Details
Muscarinic acetylcholine receptor M3P20309 Details
Muscarinic acetylcholine receptor M4P08173 Details
Muscarinic acetylcholine receptor M5P08912 Details
References
  1. Hustveit O, Maurset A, Oye I: Interaction of the chiral forms of ketamine with opioid, phencyclidine, sigma and muscarinic receptors. Pharmacol Toxicol. 1995 Dec;77(6):355-9. [PubMed:8835358 ]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Beta-arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways. Signaling activates phospholipase C and a phosphatidylinositol-calcium second messenger system that modulates the activity of phosphatidylinositol 3-kinase and promotes the release of Ca(2+) ions from intracellular stores. Affects neural activity, perception, cognition and mood. Plays a role in the regulation of behavior, including responses to anxiogenic situations and psychoactive substances. Plays a role in intestinal smooth muscle contraction, and may play a role in arterial vasoconstriction.(Microbial infection) Acts as a receptor for human JC polyomavirus/JCPyV.
Components:
NameUniProt IDDetails
5-hydroxytryptamine receptor 2AP28223 Details
5-hydroxytryptamine receptor 2BP41595 Details
5-hydroxytryptamine receptor 2CP28335 Details
References
  1. Martin LL, Bouchal RL, Smith DJ: Ketamine inhibits serotonin uptake in vivo. Neuropharmacology. 1982 Feb;21(2):113-8. [PubMed:6460944 ]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways. Signaling inhibits adenylate cyclase activity and activates a phosphatidylinositol-calcium second messenger system that regulates the release of Ca(2+) ions from intracellular stores. Plays a role in the regulation of 5-hydroxytryptamine release and in the regulation of dopamine and 5-hydroxytryptamine metabolism. Plays a role in the regulation of dopamine and 5-hydroxytryptamine levels in the brain, and thereby affects neural activity, mood and behavior. Plays a role in the response to anxiogenic stimuli.
Components:
NameUniProt IDDetails
5-hydroxytryptamine receptor 1AP08908 Details
5-hydroxytryptamine receptor 1BP28222 Details
5-hydroxytryptamine receptor 1DP28221 Details
5-hydroxytryptamine receptor 1EP28566 Details
5-hydroxytryptamine receptor 1FP30939 Details
References
  1. Martin LL, Bouchal RL, Smith DJ: Ketamine inhibits serotonin uptake in vivo. Neuropharmacology. 1982 Feb;21(2):113-8. [PubMed:6460944 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37. [PubMed:12438524 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23